MedPath

Atovaquone-resistant Plasmodium falciparum in Central Africa

Phase 4
Conditions
target disease - malaria
Registration Number
JPRN-UMIN000003813
Lead Sponsor
Aix-Marseille Universite
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
250
Inclusion Criteria

Not provided

Exclusion Criteria

signs and symptoms of severe and complicated malaria (as defined by the World Health Organization), mixed infections with other Plasmodium species, persistent vomiting, hematocrit less than 15%

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
adequate clinical and parasitological response versus treatment failure on day 28, as defined by the World Health Organization
Secondary Outcome Measures
NameTimeMethod
parasite and fever clearance times
© Copyright 2025. All Rights Reserved by MedPath